Modality
Small Molecule
MOA
WEE1i
Target
RET
Pathway
Ferroptosis
Atopic DermMelanoma
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
Feb 2024
→ Sep 2031
Phase 1Current
NCT06067931
941 pts·Melanoma
2024-02→2031-09·Recruiting
941 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-215.5y awayInterim· Melanoma
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2031-09-21 · 5.5y away
Melanoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06067931 | Phase 1 | Melanoma | Recruiting | 941 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |